MediciNova, Inc.

Equities

MNOV

US58468P2065

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 01:16:25 29/05/2024 am IST			5-day change	1st Jan Change
1.348 ^USD	+0.60%		-3.02%	-10.13%

20/05	MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 for the Prevention of Metastasis of Eye Cancer	CI
14/05	MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome	CI

MediciNova Inc. Appoints Yoshio Ishizaka to its Board of Directors

April 09, 2014 at 04:30 am IST

MediciNova Inc. announced the appointment of Mr. Yoshio Ishizaka to its Board of Directors. Mr. Ishizaka complements the MediciNova Board with 50 years of experience in marketing and product development with Toyota Motor Corporation (TMC). His international experience includes assignments in Japan, Europe and the U.S.

Latest news about MediciNova, Inc.

MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 for the Prevention of Metastasis of Eye Cancer	20/05	CI
MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome	14/05	CI
MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
MediciNova, Inc. Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166	07/05	CI
MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 for the Treatment of Macular Injury in Japan	27/03	CI
Medicinova Announces New Data and Results of Mn-166 in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology	12/03	CI
MediciNova, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/02	CI
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 for the Treatment of Macular Injury in China	17/01	CI
Top Premarket Gainers	12/01	MT
MediciNova, Inc. Announces Abstract Regarding MN-166 in Chlorine Gas-Induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology	22/12	CI
MediciNova, Inc. Receives a Notice of Decision to Grant for a New Patent Covering MN-166 for the Treatment of Progressive MS in Europe	07/12	CI
Sector Update: Health Care Stocks Lean Down Premarket Monday	20/11	MT
MediciNova Says Glioblastoma Phase 2 Trial of Therapy Combo Showed Progression-Free Survival of 44% at Six Months	20/11	MT
MediciNova, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
MediciNova Secures Patent Notice of Allowance in Canada for Amyotrophic Lateral Sclerosis Combination Treatment	11/23/11	MT
MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis in Canada	11/23/11	CI
MediciNova Says it Received $1 Million Clinical Development Milestone Payment Under Deal With Sanofi Subsidiary	05/23/05	MT
Sector Update: Health Care Stocks Gain Premarket Thursday	28/23/28	MT
MediciNova Says Ibudilast Improved Pulmonary Function in Lung Injury Study	28/23/28	MT
MediciNova, Inc. Announces Results of Studies Under BARDA Contract to Develop MN 166 as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury	28/23/28	CI
MediciNova Announces Abstract Regarding MN-166 in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology	18/23/18	CI
MediciNova Says European Patent Office Issued Notice of Intention to Grant on Macular Injury Therapy Application	17/23/17	MT
MediciNova, Inc. Receives A Notice of Intention to Grant for A New Patent Covering MN-166 for the Treatment of Macular Injury in Europe	17/23/17	CI
Sector Update: Health Care Stocks Steady Premarket Wednesday	16/23/16	MT
Fed Minutes Anticipation Lifts Exchange-Traded Funds, Equity Futures Slightly Premarket Wednesday	16/23/16	MT

Chart MediciNova, Inc.

Duration

Period

More charts

Company Profile

MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.

Sector

Biotechnology & Medical Research

Calendar

02/06/2024 - American Society of Clinical Oncology Meeting - Abstract Number: 2106

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.34 USD

Average target price

17 USD

Spread / Average Target

+1,168.66%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MEDICINOVA, INC.	-10.13%	6.57Cr
VERTEX PHARMACEUTICALS INCORPORATED	+9.85%	12TCr
REGENERON PHARMACEUTICALS, INC.	+10.64%	11TCr
BIONTECH SE	-10.92%	2.34TCr
ARGENX SE	-1.69%	2.21TCr
GENMAB A/S	-10.23%	1.83TCr
WUXI APPTEC CO., LTD.	-41.92%	1.66TCr
BEIGENE, LTD.	-15.58%	1.6TCr
NEUROCRINE BIOSCIENCES, INC.	+7.01%	1.4TCr
SAREPTA THERAPEUTICS, INC.	+17.73%	1.17TCr

Bio Therapeutic Drugs